Global impact of nirsevimab on respiratory syncytial virus: Valle d’Aosta and beyond

Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in infants, with significant morbidity and mortality worldwide.Despite advancements in medical care, RSV continues to impose a substantial economic and emotional burden on families.Current preventive measures, such as the monoclonal antibody palivizumab, are limited to high-risk populations due to cost and administration frequency.Recently, a new prophylactic agent, nirsevimab, has become available for protection of all infants and children during their first RSV season.Nirsevimab is a humanized monoclonal antibody that targets the fusion (F) protein of RSV in its prefusion conformation, a critical structure for viral infectivity.Nir